Key result
Low-dose methotrexate, low-dose colchicine, or their combination did not improve coronary endothelial function compared to placebo in patients with stable coronary artery disease.
Why the study?
Inflammation promotes CAD, but the impact of anti-inflammatory therapies on atherosclerosis-promoting processes is unknown. The authors hypothesized that anti-inflammatory approaches improve impaired coronary endothelial function in stable CAD.
Does low dose methotrexate, low dose colchicine, or their combination improve coronary endothelial function in patients with stable coronary artery disease?
RCT (n=94)
Double-blind
2x2 factorial
No
Does low dose methotrexate, low dose colchicine, or their combination improve coronary endothelial function in patients with stable coronary artery disease?
Low-dose methotrexate, colchicine, or their combination did not improve coronary endothelial function or systemic inflammatory markers in patients with stable coronary artery disease.
Answers are grounded in this paper and cite their sources.
No benefit on coronary endothelial function with low-dose methotrexate or colchicine in stable CAD; challenges anti-inflammatory strategies for endothelial dysfunction.
Aims: Inflammation plays a critical role in the pathogenesis of coronary artery disease (CAD), however the impact of anti-inflammatory therapies to reduce those processes which promote atherosclerosis in CAD patients is unknown. We aimed to test the hypothesis that anti-inflammatory approaches improve impaired coronary endothelial function (CEF), a driver of coronary atherosclerosis, in stable CAD patients. Methods and Results: We performed a single-center, randomized, placebo-controlled, double-blinded trial to assess whether low dose methotrexate (MTX), low dose colchicine (LDC), and/or their combination (MTX+LDC), improves CEF using non-invasive MRI measures in patients with stable CAD ( N = 94). The primary endpoint was the MRI-detected change in coronary cross-sectional area from rest to isometric handgrip exercise (IHE), a predominantly nitric oxide-dependent endothelial dependent stressor. Coronary and systemic endothelial endpoints, and serum inflammatory markers, were collected at baseline, 8 and 24 weeks. Anti-inflammatory study drugs were well-tolerated. There were no significant differences in any of the CEF parameters among the four groups (MTX, LDC, MTX+LDC, placebo) at 8 or 24 weeks. Serum markers of inflammation and systemic endothelial function measures were also not significantly different among the groups. Conclusion: This is the first study to examine the effects of the anti-inflammatory approaches using MTX, LDC, and/or the combination in stable CAD patients on CEF, a marker of vascular health and the primary endpoint of the study. Although these anti-inflammatory approaches were relatively well-tolerated, they did not improve coronary endothelial function in patients with stable CAD. Clinical Trial Registration: www.clinicaltrials.gov , identifier: NCT02366091.
No takes yet. Share an insight, caveat, or question.
Hays et al. (2021) conducted an RCT in Stable coronary artery disease (n=94). Methotrexate, Colchicine, or combination vs. Placebo was evaluated on Percentage change in coronary cross-sectional area from rest to isometric handgrip exercise at 8 weeks (p=NS). Low-dose methotrexate, low-dose colchicine, or their combination did not improve coronary endothelial function compared to placebo in patients with stable coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: